"We believe that this transaction is also a compelling financial opportunity that delivers significant value to our investors who have supported our evolution to becoming a valued player in the urology market." Cogentix Medical's path to a nearly quarter-of-a-billion sale was by no means easy. The company, originally known as Uroplasty Inc., was incorporated in the state of Minnesota in 1992. After a merger deal at the end of 2014 with New York-based Vision-Sciences Inc., the company — now known as Cogentix Medical — experienced a proxy fight in 2016 that ended with its then-CEO Robert Kill and two board members stepping down. The fight largely involved disagreements between Kill and another board member Lewis Pell, who owned a large share of the company. Following the departures, the Nasdaq threatened to pull Cogentix Medical shares off the stock exchange for not having enough independent directors on its board. The company responded by essentially killing two birds with one stone.